Vipivotide tetraxetan

Star0

DB28386InvestigationalSmall molecule

Vipivotide tetraxetan: Overview.

Mechanism: Pharmacologically active on Glutamate carboxypeptidase 2
Curator reviewed
Formula / weight: C₄₉H₇₁N₉O₁₆ · 1042.154 g/mol (avg)
Code names: DKFZ-PSMA-617 · PSMA-617

Resolves to

Compound

UNII4YM1W0EGQ5CAS1702967-37-0ChEMBLCHEMBL4594280ChEBI757783

Clinical / RWD

RxNorm2597054

Structure

InChIKeyJBHPLHATEXGMQR-LFWIOBPJSA-NSMILES

OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)[C@H](CC1=CC2=CC=CC=C2C=C1)NC(=O)[C@H]1CC[C@H](CNC(=O)CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC2)CC1)C(O)=O)C(O)=O

Targets

Q04609FOLH1

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Vipivotide tetraxetan, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account